Plasma Exchange for Longevity: The Science of Young Plasma Infusion and Age Reversal

## The Blood of Youth: Rediscovering Parabiosis in Modern Medicine

The search for the fountain of youth has taken many forms throughout human history, but few approaches have generated as much scientific excitement—and controversy—as the concept that young blood might reverse aging. The modern incarnation of this ancient quest, therapeutic plasma exchange (TPE), represents one of the most aggressive and scientifically compelling interventions in the longevity arsenal.

Bryan Johnson, the tech entrepreneur who has become the world's most public longevity biohacker, has made therapeutic plasma exchange a cornerstone of his Blueprint protocol. Johnson doesn't merely dabble in this intervention; he has undergone multiple rounds of plasma exchange, meticulously tracking biomarkers to assess its impact on his biological age. His approach exemplifies the Johnson Pillar philosophy: rigorous measurement, systematic intervention, and willingness to pursue treatments at the frontier of medical science.

The scientific foundation for plasma exchange as an age-reversal therapy originates from parabiosis experiments—studies where the circulatory systems of young and old animals are surgically joined. These experiments, dating back to the 1950s but refined dramatically in recent decades, consistently demonstrate that exposure to young blood rejuvenates aged tissues. Old mice connected to young partners show improved muscle regeneration, enhanced neurogenesis, reduced cardiac hypertrophy, and even partial reversal of cognitive decline.

The critical question—and the basis for therapeutic plasma exchange—is what specifically in young blood drives these rejuvenating effects, and whether removing aged plasma components while replacing them with healthier alternatives can replicate the benefits without the need for ethically problematic human parabiosis.

The Science of Aging Plasma: What Goes Wrong

To understand why plasma exchange might work, we must first examine what happens to blood plasma as we age. Blood plasma, the liquid component of blood comprising roughly 55% of total blood volume, serves as the medium through which cells communicate, nutrients are transported, and waste products are removed. Its composition profoundly influences cellular function throughout the body.

The Inflammatory Milieu of Aged Plasma

Aging transforms blood plasma from a regenerative medium into a pro-inflammatory, pro-senescent environment. Research published in *Nature Aging* and *Cell Metabolism* has identified multiple molecular changes that characterize aged plasma:

Elevated Inflammatory Cytokines: Aged plasma shows markedly elevated levels of inflammatory signaling molecules including IL-6, TNF-alpha, and IL-1-beta. These cytokines drive systemic inflammation—a hallmark of aging dubbed "inflammaging"—that accelerates cellular senescence, impairs tissue repair, and contributes to virtually every age-related disease.

Senescence-Associated Secretory Phenotype (SASP) Factors: Senescent cells—cells that have stopped dividing but refuse to die—accumulate with age and secrete a toxic cocktail of inflammatory factors. These SASP components circulate in aged plasma, spreading senescence to neighboring tissues and perpetuating the cycle of cellular aging.

Pro-Clotting Factors: Coagulation markers including fibrinogen, D-dimer, and von Willebrand factor increase with age, contributing to the elevated cardiovascular risk that characterizes aging. Aged plasma promotes a pro-thrombotic state that damages endothelium and impairs microcirculation.

Metabolic Waste Accumulation: Advanced glycation end products (AGEs), oxidized lipids, and damaged proteins accumulate in aged plasma. These molecules cross-link extracellular matrix components, impair cellular signaling, and directly damage tissues exposed to their effects.

Growth Factor Dysregulation: While some growth factors decline with age (contributing to tissue atrophy), others show inappropriate elevation. The net effect is disrupted tissue homeostasis—some tissues atrophy while others undergo pathological growth or fibrosis.

The Albumin Hypothesis

Albumin, the most abundant protein in blood plasma, deserves special attention in any discussion of therapeutic plasma exchange. This 66.5 kDa protein has multiple functions essential for health:

Osmotic Regulation: Albumin maintains plasma oncotic pressure, preventing fluid from leaking into tissues and causing edema. Each gram of albumin holds approximately 18 ml of fluid within the vascular space.

Transport Function: Albumin transports fatty acids, bilirubin, calcium, hormones (including thyroid hormones and cortisol), and numerous drugs throughout the body. Its binding capacity ensures these molecules remain bioavailable yet protected from degradation.

Antioxidant Properties: Albumin contains a free thiol group (cysteine-34) that scavenges reactive oxygen species, making it one of the body's primary circulating antioxidants. Aged, oxidized albumin loses this protective capacity.

Anti-Inflammatory Effects: Albumin binds and neutralizes inflammatory molecules, including endotoxin and pro-inflammatory cytokines. It also stabilizes cell membranes and reduces complement activation.

Critical Finding: Albumin Declines and Oxidizes with Age

Plasma albumin levels decrease by approximately 10-15% between age 20 and age 80. More importantly, the remaining albumin becomes increasingly oxidized and glycated, losing its functional capacity. Studies demonstrate that oxidized albumin not only fails to provide antioxidant protection but may actually become pro-inflammatory itself.

This dual hit—reduced quantity and impaired quality of albumin—is hypothesized to contribute significantly to the pathology of aged plasma. Therapeutic plasma exchange addresses both aspects by removing oxidized, dysfunctional albumin and replacing it with fresh, functional albumin from donor plasma or recombinant sources.

Therapeutic Plasma Exchange: The Mechanism

Therapeutic plasma exchange is an established medical procedure with over 50 years of clinical use, though its application to longevity is novel. The procedure involves:

The Procedure

1. Blood Withdrawal and Separation: Blood is drawn from the patient through a catheter (typically placed in a large peripheral vein or central access). An apheresis machine separates whole blood into its components using centrifugal force or membrane filtration.

2. Plasma Removal: The plasma component—containing the aged proteins, inflammatory factors, and metabolic waste—is diverted and discarded. Typically, 2-4 liters of plasma are removed during a single session, representing a substantial fraction of total circulating plasma volume.

3. Replacement Infusion: The removed plasma is replaced with an equivalent volume of replacement fluid. Options include: - Albumin solution (4-5% albumin in saline) - Fresh frozen plasma (FFP) from young, screened donors - Combinations of albumin and donor plasma

4. Cellular Component Return: The cellular components (red blood cells, white blood cells, platelets) are returned to the patient along with the replacement fluid, minimizing blood loss and preserving hematocrit.

A complete exchange session typically requires 2-3 hours and removes approximately 65-70% of circulating plasma components. Multiple sessions may be performed over weeks or months depending on the protocol.

Quantity and Frequency

Johnson's Protocol: Bryan Johnson has reported undergoing therapeutic plasma exchange approximately every 6 months. Each session exchanges 2-3 liters of plasma, removing substantial quantities of aged proteins and inflammatory mediators while introducing fresh albumin.

Frequency Logic: Plasma proteins have varying half-lives, but albumin turns over relatively slowly (approximately 20-25 days). However, inflammatory cytokines and acute phase reactants regenerate rapidly. The 6-month interval Johnson employs likely reflects a balance between therapeutic benefit, cost considerations, and practical logistics.

The Evidence: Parabiosis and Plasma Exchange Studies

The scientific case for plasma exchange as a longevity intervention rests on a foundation of animal studies, emerging human trials, and mechanistic research that continues to evolve rapidly.

Parabiosis Experiments: Proof of Concept

Heterochronic Parabiosis: Landmark studies at Stanford University and institutions worldwide have demonstrated that connecting the circulatory systems of young and old mice produces striking rejuvenation of aged tissues:

Muscle: Aged mice connected to young partners show enhanced muscle regeneration, increased satellite cell activation, and improved strength
Brain: Neurogenesis increases in the hippocampus, and cognitive performance improves on memory tasks
Heart: Cardiac hypertrophy reverses, and cardiac function improves
Liver: Hepatic regeneration capacity improves, and metabolic function normalizes

The Role of Young Plasma Specifically: Critically, later experiments demonstrated that transfusing young plasma alone—without the complexity of surgical parabiosis—produces many of the same benefits. This finding established that soluble factors in young plasma drive rejuvenation, opening the door to therapeutic plasma exchange as a practical intervention.

Young Plasma Clinical Trials in Humans

While therapeutic plasma exchange is FDA-approved for numerous conditions (including neuromuscular disorders, autoimmune diseases, and TTP), its use for age reversal remains investigational. However, early human trials have shown promise:

Alzheimer's Disease Studies: Multiple clinical trials have investigated young plasma infusion for Alzheimer's disease. While results have been mixed, some studies show stabilization of cognitive decline and improvement in functional measures. The plasma exchange component—the removal of aged plasma in addition to infusion of young plasma—appears particularly important.

Ambrosia and Young Plasma Clinics: Several commercial enterprises have offered young plasma transfusions, though regulatory pressure has limited their operation. Early adopters and case studies report improvements in energy, cognitive clarity, and biomarkers, though rigorous controlled trials remain limited.

Albumin Replacement Studies

Research specifically examining albumin replacement—without young plasma factors—has also shown benefits:

Critically Ill Patients: In sepsis and critical illness, albumin replacement improves outcomes and reduces inflammation. While these populations differ from healthy aging individuals, the mechanisms—restoring antioxidant capacity, improving oncotic pressure, and reducing inflammatory load—are relevant to aging.

Aging Populations: Studies in elderly patients with hypoalbuminemia demonstrate that albumin replacement improves functional status, reduces hospitalization, and lowers inflammatory markers. The hypothesis that healthy aging individuals might benefit from albumin optimization regardless of serum levels remains under investigation.

The Young Plasma Factors: Molecular Candidates

What specific molecules in young plasma drive rejuvenation? Research has identified several promising candidates that may underlie the effects observed in parabiosis and plasma exchange:

Growth Differentiation Factor 11 (GDF11)

GDF11, a member of the TGF-beta superfamily, emerged as a leading candidate when research demonstrated that GDF11 levels decline with age and that supplementation rejuvenates aged cardiac and skeletal muscle.

The Controversy: Subsequent studies challenged the initial findings, suggesting that reported effects might reflect assay artifacts or that GDF11 actually increases with age. The scientific community remains divided, with ongoing research attempting to resolve these discrepancies.

Current Status: While GDF11 may not be the single "youth factor" originally hypothesized, it remains biologically active and relevant to tissue homeostasis. Its precise role in plasma exchange benefits requires further elucidation.

Tetranectin (CLEC3B)

Tetranectin, a plasminogen-binding protein, shows higher levels in young plasma and has been implicated in neurogenesis and tissue repair. Research published in *Nature Communications* identified tetranectin as one factor that promotes neural stem cell proliferation.

Oxytocin

The "love hormone" plays roles beyond social bonding, including muscle regeneration and metabolic regulation. Plasma oxytocin levels decline with age, and supplementation shows promise in preclinical models of sarcopenia.

Thrombospondin-4 (THBS4)

This matricellular protein, elevated in young plasma, promotes cardiac regeneration and tissue repair. Research suggests THBS4 may mediate some of the cardiac benefits observed in parabiosis.

Exosomes and Microvesicles

Young plasma contains extracellular vesicles—exosomes and microvesicles—that transport miRNAs, proteins, and lipids between cells. These vesicles may carry rejuvenating signals that influence gene expression in aged tissues. Plasma exchange may function partly by introducing beneficial extracellular vesicles while removing aged, damaged vesicles.

Risks and Considerations

Therapeutic plasma exchange, while established as a medical procedure, is not without risks. Anyone considering this intervention should understand the potential complications:

Procedure Risks

Hypotension: Fluid shifts during plasma exchange can cause blood pressure drops, potentially causing dizziness or fainting. Proper fluid management minimizes this risk.

Electrolyte Imbalances: Removal of plasma electrolytes (calcium, magnesium, potassium) requires replacement and monitoring. Citrate anticoagulation can cause hypocalcemia during the procedure.

Allergic Reactions: Replacement albumin or donor plasma can trigger allergic reactions ranging from mild hives to severe anaphylaxis. Pre-medication with antihistamines reduces risk.

Infection: Central line placement carries infection risk. Strict sterile technique is essential.

Coagulopathy: Removal of coagulation factors requires monitoring and may necessitate replacement with fresh frozen plasma rather than albumin alone.

Long-Term Considerations

Immune Modulation: Regular plasma exchange could theoretically affect immune function, though long-term studies in healthy individuals are lacking. The removal of antibodies and immunoglobulins may have unintended consequences.

Donor Plasma Risks: Use of donor plasma introduces the risk of infectious disease transmission (despite screening) and potential immune reactions to donor proteins.

Cost and Access: Therapeutic plasma exchange costs $5,000-$15,000 per session, making it accessible primarily to those with substantial resources. This economic reality limits widespread adoption and systematic study.

Ethical Concerns: The commercialization of young blood has raised ethical concerns about exploitation of young donors and equity of access to potential longevity therapies.

The Bryan Johnson Blueprint Approach

Bryan Johnson's implementation of therapeutic plasma exchange exemplifies his systematic, measurement-driven philosophy:

Protocol Details

Frequency: Approximately every 6 months
Volume: 2-3 liters exchanged per session
Replacement: Combination approach using albumin and carefully screened donor plasma
Monitoring: Comprehensive biomarker assessment before and after each session, tracking:
Inflammatory markers (IL-6, TNF-alpha, CRP)
Albumin levels and oxidative status
Lipid profiles
Metabolic markers
Biological age clocks (epigenetic and proteomic)

Synergistic Interventions

Johnson doesn't view plasma exchange in isolation but integrates it into a comprehensive longevity protocol:

Plasmapheresis + Senolytics: Removing senescent cell burden through senolytics (like fisetin, quercetin + dasatinib) prior to plasma exchange may amplify benefits by reducing the source of SASP factors that contaminate plasma.

Optimized Nutrition Pre-Exchange: Johnson maintains strict nutritional protocols in the weeks preceding plasma exchange to minimize inflammatory load and optimize baseline markers. This includes elimination of processed foods, alcohol, and inflammatory triggers.

Post-Exchange Recovery Protocol: Following plasma exchange, Johnson implements enhanced recovery strategies including: - Strict sleep optimization (8+ hours with precise timing) - Light movement and walking to promote circulation - Continued elimination of inflammatory triggers - Enhanced hydration and electrolyte balance - Monitoring for any adverse reactions

Biomarker Tracking: Johnson's team tracks multiple biomarkers to assess the impact of each plasma exchange session: - Albumin levels (pre/post) - Inflammatory markers (CRP, IL-6, TNF-alpha) - Oxidative stress markers - Lipid profiles - Liver and kidney function - Complete blood counts - Epigenetic clock assessments

This rigorous tracking enables data-driven decisions about protocol modifications and validates whether the intervention produces measurable biological improvements.

Practical Implementation: Building Your Protocol

For those considering therapeutic plasma exchange, the following framework provides a starting point for working with qualified medical providers:

Prerequisites

Medical Evaluation:
Comprehensive metabolic panel
Cardiovascular assessment
Infectious disease screening
Hematological evaluation
Assessment of current inflammatory status

Contraindications:
Severe anemia
Active bleeding disorders
Severe cardiovascular instability
Severe allergic reactions to albumin or blood products
Active infection

Protocol Design

Step 1: Initial Assessment Baseline biomarker measurement including: - Complete metabolic panel - Lipid panel - Inflammatory markers (CRP, IL-6, TNF-alpha) - Albumin and total protein - Ferritin and iron studies - Coagulation studies - Complete blood count

Step 2: First Session
Exchange volume: 2-3 liters (individualized based on body weight and tolerance)
Replacement: 5% albumin solution or combination with fresh frozen plasma
Monitoring: Continuous vital signs, periodic lab assessment
Duration: 2-3 hours

Step 3: Follow-Up Assessment
Post-exchange biomarkers (7-14 days post-procedure)
Symptom assessment (energy, cognitive clarity, recovery)
Comparison to baseline to assess response

Step 4: Maintenance Schedule
Initial series: 3 sessions over 3-6 months
Ongoing maintenance: Every 6-12 months based on response and biomarker trends
Adjustment of protocol based on individual response

Integration with Longevity Strategies

Plasma exchange should be viewed as one component of a comprehensive longevity protocol:

Foundation:
Optimized nutrition (anti-inflammatory, nutrient-dense)
Quality sleep (7-9 hours, consistent timing)
Regular exercise (resistance training, zone 2 cardio)
Stress management (meditation, breathwork)
Elimination of toxic exposures (alcohol, smoking, processed foods)

Synergistic Interventions:
Senolytics for cellular senescence clearance
NAD+ optimization for cellular energy
Hormone optimization (if indicated)
Peptide therapy for tissue repair
Supplementation for inflammation reduction

Monitoring:
Regular biomarker assessment
Biological age tracking
Body composition analysis
Functional capacity testing
Cognitive assessment

The Future of Plasma Exchange and Longevity

The field of plasma-based longevity interventions is evolving rapidly. Several promising directions may reshape therapeutic approaches in coming years:

Fractionated Plasma Components

Rather than transfusing whole plasma, researchers are identifying specific fractions or purified factors that drive rejuvenation. This precision approach could: - Eliminate risks associated with donor plasma - Standardize dosing of active components - Reduce costs through targeted therapy - Enable oral or subcutaneous administration

Candidates include purified albumin, specific growth factors, exosome preparations, and synthetic mimics of youth-associated proteins.

Autologous Plasma Optimization

Instead of introducing donor plasma, future protocols may focus on optimizing and re-infusing one's own plasma: - Plasma filtration to remove inflammatory factors - Ex vivo rejuvenation treatments - Addition of protective factors - Re-infusion of optimized autologous plasma

This approach eliminates donor risks and immune concerns while still benefiting from plasma exchange principles.

Advanced Apheresis Technologies

Next-generation apheresis devices may enable: - Selective removal of specific proteins or factors - Continuous rather than intermittent treatment - Home-based therapy with reduced cost and increased access - Personalized protocols based on real-time biomarker feedback

Regulatory Pathways and Clinical Trials

The FDA and international regulators are increasingly interested in aging as a modifiable condition. Formal clinical trials investigating plasma exchange for age-related dysfunction—rather than specific diseases—may establish regulatory pathways for widespread clinical adoption.

Protocols & Takeaways

The Johnson-Inspired Plasma Exchange Protocol

Pre-Protocol Optimization (2-4 weeks): 1. Eliminate alcohol, processed foods, and inflammatory triggers 2. Optimize sleep (8+ hours, consistent schedule) 3. Maintain regular exercise (but avoid overtraining) 4. Hydrate adequately (3+ liters daily) 5. Consider anti-inflammatory supplementation (omega-3s, curcumin)

Treatment Day Protocol: 1. Fasting: Light meal 4+ hours before procedure; hydrate well 2. Supplementation: Hold morning supplements unless directed otherwise 3. During procedure: Stay relaxed; practice breathing exercises 4. Post-procedure: Light meal 1-2 hours after; continue hydration 5. Activity: Rest day; light walking only

Post-Exchange Recovery (7-14 days): 1. Continue strict sleep optimization 2. Maintain anti-inflammatory nutrition 3. Light to moderate exercise only 4. Enhanced hydration and electrolytes 5. Avoid alcohol and excessive stress 6. Monitor for any adverse reactions

Maintenance Schedule:
Initial series: 3 sessions over 3-6 months
Ongoing: Every 6-12 months based on biomarker response
Adjustment based on individual results and tolerance

Key Scientific Principles

1. Aged plasma carries an inflammatory burden. Removing aged plasma eliminates circulating inflammatory cytokines, SASP factors, and metabolic waste products that drive cellular aging.

2. Albumin function degrades with age. Albumin replacement restores antioxidant capacity, improves transport function, and provides anti-inflammatory benefits.

3. Young plasma contains rejuvenating factors. Growth factors, exosomes, and signaling molecules in young donor plasma may activate regenerative pathways in aged tissues.

4. Parabiosis proves the concept. Animal studies demonstrate that exposure to young circulation rejuvenates aged tissues—plasma exchange attempts to replicate this effect therapeutically.

5. Systemic milieu matters. The composition of blood plasma creates an environment that either promotes or inhibits cellular health throughout the body.

6. Individual response varies. Genetic factors, baseline health status, and existing inflammatory burden influence response to plasma exchange.

7. Integration amplifies benefits. Plasma exchange works best as part of a comprehensive longevity protocol addressing all pillars of health.

8. Measurement drives optimization. Rigorous biomarker tracking enables data-driven decisions about frequency, volume, and protocol modifications.

9. Risks require respect. While generally safe, plasma exchange carries procedural risks and requires qualified medical supervision.

10. The field is evolving. Current protocols represent early-stage application; future refinements may include targeted factors, optimized schedules, and personalized approaches.

The Johnson-Inspired Assessment Protocol

Baseline Biomarkers (Pre-Exchange):
Albumin (target: >4.0 g/dL)
CRP (target: <1.0 mg/L)
IL-6 (target: <3.0 pg/mL)
TNF-alpha (target: <8.0 pg/mL)
Fibrinogen (target: 200-400 mg/dL)
Lipid panel (assess cardiovascular risk)
Complete metabolic panel
CBC with differential

Post-Exchange Assessment (7-14 days):
Repeat all baseline biomarkers
Assess change in inflammatory markers
Evaluate albumin levels and function
Monitor for adverse effects
Subjective assessment (energy, cognition, recovery)

Long-Term Tracking:
Quarterly biomarker panels
Annual biological age assessment
Body composition analysis
Functional capacity testing
Cognitive performance metrics

Safety Considerations

Before Undergoing Plasma Exchange:
Consult with physician familiar with your medical history
Understand procedure risks and benefits
Verify facility credentials and experience
Establish emergency protocols
Ensure appropriate monitoring capabilities

Red Flags Requiring Immediate Medical Attention:
Severe allergic reaction (hives, difficulty breathing, swelling)
Chest pain or cardiac symptoms
Severe dizziness or loss of consciousness
Signs of infection (fever, chills, localized pain)
Unusual bleeding or bruising

Conclusion: The Plasma Frontier

Therapeutic plasma exchange for longevity sits at the intersection of established medical technology and cutting-edge aging science. While parabiosis experiments proved that young blood rejuvenates aged tissues, translating this insight into practical human therapy remains a work in progress.

Bryan Johnson's adoption of plasma exchange exemplifies the aggressive, measurement-driven approach that characterizes the Johnson Pillar. By systematically tracking biomarkers, optimizing protocols based on data, and integrating plasma exchange into a comprehensive longevity strategy, Johnson pushes the boundaries of what's possible in age reversal.

The scientific evidence supporting plasma exchange is compelling but incomplete. Animal studies demonstrate clear rejuvenating effects; human trials show promise but require further validation. The mechanisms—whether through albumin replacement, removal of inflammatory factors, or introduction of youth-associated signaling molecules—continue to be elucidated.

For those considering this intervention, several principles should guide decision-making:

Medical Supervision Is Essential: Plasma exchange is a medical procedure requiring qualified providers, appropriate facilities, and proper monitoring.

Integration Amplifies Benefits: Plasma exchange works best as part of a comprehensive protocol addressing nutrition, sleep, exercise, stress, and other longevity pillars.

Measurement Enables Optimization: Rigorous biomarker tracking separates effective protocols from expensive placebos.

Individual Variation Is Real: Response to plasma exchange varies based on genetics, baseline health, and existing inflammatory burden.

The Field Is Evolving: Current protocols represent early-stage application; future refinements will likely improve efficacy and accessibility.

Risk-Benefit Analysis Required: The potential benefits of plasma exchange must be weighed against procedural risks, costs, and the current state of evidence.

The quest to slow and potentially reverse aging drives innovation across multiple scientific disciplines. Therapeutic plasma exchange—removing aged plasma and replacing it with fresh albumin or young donor plasma—represents one of the most direct attempts to address the systemic inflammatory environment that characterizes aging.

Whether plasma exchange becomes a routine component of longevity medicine or gives way to more targeted interventions remains to be seen. For now, it stands as a testament to the extraordinary measures some are willing to pursue—and invest in—in the search for extended healthspan and, ultimately, age reversal.

The blood that flows through your veins carries more than oxygen and nutrients. It carries information—signals that tell your cells whether to regenerate or senesce, whether to repair or decline. Therapeutic plasma exchange attempts to change that message, replacing aging's pro-inflammatory signals with the regenerative milieu of youth. The science is advancing. The protocols are being refined. And for those at the forefront of longevity biohacking, the frontier of plasma-based age reversal offers a tantalizing glimpse of what may be possible.

---

The Online BioHack Plasma Optimization Approach

At Online BioHack, we provide comprehensive assessment and coordination of advanced longevity protocols:

Biomarker Assessment: Comprehensive inflammatory, metabolic, and aging marker panels
Protocol Design: Personalized plasma exchange schedules based on individual biology
Integration Services: Coordination of plasma exchange with senolytics, NAD+ therapy, and other interventions
Monitoring Programs: Ongoing biomarker tracking and protocol optimization
Referral Network: Coordination with qualified apheresis centers and longevity physicians
Educational Resources: Evidence-based guidance on emerging plasma-based therapies

Contact us: (555) 246-4225 | hello@onlinebiohack.com

---

*The statements in this article have not been evaluated by the FDA. Therapeutic plasma exchange for longevity is an investigational application requiring medical supervision. This protocol is for educational purposes and should be implemented only under the guidance of qualified healthcare providers.*